Participated · Equity · Feb 2024

Very Group is a Merseyside-based online retail and finance group fronted by actress Michelle Keegan that sells clothes, footwear and electronics. The business is owned by the Barclay family and was created from the former Littlewoods and Shop Direct businesses by Sir David and Sir Frederick Barclay. Very is currently loss-making: it posted a half-year loss of £2 million, having made a £2.1 million profit at the same point in 2023. The group has begun a search for a chairman after Dirk Van den Berghe said he will step down; Aidan Barclay will act as chairman until the role is filled. Carlyle and Abu Dhabi-based IMI have provided recent funding and will take board seats, a move described in the article as a boost for the Barclay family amid wider scrutiny of their plans to sell The Telegraph.

Participated · Equity · Nov 2014

Quanta Dialysis Technologies develops the Quanta Dialysis System to transform kidney care by enabling dialysis across multiple care settings. The system provides clinical versatility to perform intermittent hemodialysis (IHD), sustained low efficiency dialysis (SLED) and CRRT without bags, and in 2024 received FDA clearance for home hemodialysis with a high dialysate flow (500 mL/min). The device is designed to be operated by a broad range of users to bring dialysis directly to patients. Led by CEO Alejandro Galindo and based in Warwick, UK, the company aims to make dialysis accessible to every patient, in every setting. Quanta recently closed a Series E raising over $60M to support its US commercial expansion. The company plans to continue investing in innovation within the sector and scale its commercial footprint with support from new and existing investors. Quanta’s lead product, SC+, is a small, portable hemodialysis system that delivers the performance and dose equivalence of larger traditional machines while offering on‑demand dialysate production, high dialysate flow rates, digital connectivity and ease of use. The system uses a patented disposable cartridge for dialysate fluid management and pairs with a companion water‑purification module to create an all‑in‑one mobile stack that can run on a standard water supply. SC+ is FDA 510(k) cleared in the U.S. for use in acute and chronic care facilities and is CE marked in the U.K., where it has been used from ICU to clinic to the home. Quanta plans to scale global operations with a focus on the United States, investing in manufacturing, sales and customer service to support current approvals and market penetration. The company is preparing to launch a study to support future FDA clearance for in‑home use. The market opportunity is sizable, with a U.S. total addressable market projected to exceed $12 billion. The company is trans‑Atlantic, headquartered in the U.K. with operations in the U.S., and is now better capitalized following a major Series D raise. Quanta Dialysis Technologies develops SC+, a compact haemodialysis system designed for use in clinics and the home to empower patients to control their renal replacement therapy. The device uses a patented design that conducts all dialysate fluid management on a small, lightweight, disposable cartridge. SC+ is CE marked and has been piloted with the NHS, demonstrating clinical efficacy and performance compatible with traditional in-centre regimens. The company plans a UK commercial launch of SC+ and intends to submit a 510(k) to the FDA later this year. Quanta is led by CEO John E. Milad and was founded in 2008 in Alcester, Warwickshire, UK. The firm recently completed a first closing of Series C financing to support these plans. Quanta Fluid Solutions develops advanced haemodialysis systems, including its CE-marked portable, compact cartridge-based system called SC+. The company aims to expand its product line by developing a new nocturnal haemodialysis product concept using its cartridge platform. Funds from a £1.85M i4i award will support that development and advanced multi-physics modelling work. Quanta is collaborating with Professor William Zimmerman (Sheffield University) and Europlaz Technologies Ltd to advance cartridge technologies and modelling. Founded in 2008 as a spin-out from IMI plc, the company is based in Alcester, UK. Quanta has previously received funding from venture investors including NBGI Ventures, Wellington Partners, Seroba Kernel, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company. Quanta Fluid Solutions develops SC+, a portable, compact haemodialysis system intended for use in clinics and the home. The company is led by CEO John E. Milad and is based in Alcester, UK. It was founded in 2008 as a spinout from FTSE 100 engineering company IMI plc. Quanta focuses on enabling dialysis outside traditional centres by delivering a compact, clinic- and home-capable platform. The company closed approximately £27m in funding. It intends to use the proceeds for the clinical introduction and commercial launch of SC+.